Quantcast

Pfizer 1Q profit drops 15 pct due to lower sales

Published May 5, 2014 10:23 am

This is an archived article that was published on sltrib.com in 2014, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

New York • The drugmaker Pfizer says its first-quarter profit dropped 15 percent due to cheaper generic competition that continues to reduce sales of its multiple medicines and the end of some partnerships with other drug makers.

The maker of Viagra says net income was $2.33 billion, or 36 cents per share, for the January-March period. That's down from $2.75 billion, or 38 cents per share, a year earlier.

Excluding one-time charges, income was 57 cents per share. Analysts surveyed by FactSet expected 55 cents per share.

Revenue totaled $11.35 billion, down 9 percent. Analysts expected $12.08 billion.

Pfizer, which recently has made three unsuccessful offers to acquire rival AstraZeneca Plc, confirmed its 2014 profit forecast for earnings per share of $2.20 to $2.30 and revenue of $49.2 billion to $52.3 billion.

 

 


USER COMMENTS
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
comments powered by Disqus